MUNICH--(BUSINESS WIRE)--Brainlab AG and SurgiVision, Inc. today announced a collaboration aimed at integrating SurgiVision’s ClearPoint® product line with Brainlab’s iMRI product line, with particular focus on local delivery of drugs and other therapeutic agents to precision targets in the brain under magnetic resonance imaging (MRI) guidance. Brainlab and SurgiVision believe the integration of their technologies will allow patient-specific treatment planning, simplified clinical workflows and optimal delivery of drugs to the brain. Under the terms of the agreement, Brainlab also received the right to sell SurgiVision’s ClearPoint product line, including the right to exclusively sell ClearPoint products in the neurological drug delivery field, and Brainlab made an investment into SurgiVision. SurgiVision will continue to sell its ClearPoint product line directly for all applications outside the neurological drug delivery field.
